AIMT Aimmune Therapeutics Inc.

23.72
+0.79  (+3%)
Previous Close 22.93
Open 22.91
Price To Book 5.95
Market Cap 1469886582
Shares 61,968,237
Volume 520,776
Short Ratio
Av. Daily Volume 706,554

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 enrollment has commenced - noted June 5, 2017. Data due 1H 2019.
AR101 ARTEMIS
Peanut Allergy
Phase 3 data released November 8, 2018 noted no serious adverse events
AR101 RAMSES
Peanut Allergy
BLA filing announced December 21, 2018. Phase 3 data to be presented February 24, 9:45 a.m at AAAAI Annual Meeting.
AR101
Peanut Allergy
Phase 2 trial to be initiated 1H 2019.
AR 201
Egg Allergy
Phase 2 trial to be initiated 2H 2019.
AR 301
Walnut Allergy
Phase 2 trial initiation announced October 15, 2018.
AR101 with adjunctive dupilumab
Peanut Allergy
Phase 3 initiation announced December 19, 2018.
AR101 POSEIDON
Peanut Allergy

Latest News

  1. Aimmune Therapeutics to Host Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2018 Financial Results and Recent Operational Highlights
  2. Trading Notes for Select Stocks
  3. Aimmune Therapeutics to Present AR101, OIT and Peanut Allergy Data at 2019 AAAAI Annual Meeting
  4. 6 Biotech Stocks to Watch Now
  5. 3 Top Biotech Stocks to Buy Right Now
  6. 3 Biotech Stocks That Could Be Slapped by the U.S. Government Shutdown
  7. 3 Potential New Drugs Held Up by the Shutdown
  8. Aimmune Therapeutics Appoints Andrew Oxtoby as Chief Commercial Officer
  9. Today's Research Reports on Trending Tickers: Aimmune Therapeutics and Mirati Therapeutics
  10. Jim Cramer Shares His Thoughts On Alibaba, Dynavax, Starbucks And More
  11. This Under-the-Radar Biotech Stock Is My Top Pick for 2019
  12. Aimmune Therapeutics and KKR Enter into $170M Loan Agreement to Fund AR101 Commercialization and Pipeline Advancement
  13. Investor Expectations to Drive Momentum within L3 Technologies, The Goldman Sachs Group, Genuine Parts, Bruker, Omeros, and Aimmune Therapeutics — Discovering Underlying Factors of Influence
  14. Aimmune Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference on Monday, January 7th
  15. Aimmune Therapeutics Submits BLA to FDA for AR101 for the Treatment of Peanut Allergy in Children and Adolescents Ages 4–17
  16. Why Tilray, Fortuna Silver Mines, and Aimmune Therapeutics Jumped Today
  17. These 4 Biotech Stocks are Picking Up Speed
  18. Sell-Side Slashes DBV Tech Price Targets After Withdrawal Of BLA For Peanut Allergy Immunotherapy
  19. Aimmune Therapeutics Announces IND Filing for AR201 for Egg Allergy and Exclusive Supply Agreement with Michael Foods